Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 3 open-market purchases and 0 sales; 171 institutions reported holding it in 13F filings for Q3 2026, worth $167.0M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 18, 2026
- $110.0M
- Insider buysLast 90 days, $27.1K in total
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, −40 vs. previous quarter
- 171
- 13F valueReported value at the end of Q3 2026
- $167.0M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- −100.0% year over year
- Net income, FY2025
- -$66.5M
- No comparable prior period
- Free cash flow, FY2025
- -$49.2M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 40.8M
- Shares sold short
- Change
- −1.06M
- −2.5% vs. previous
- Days to cover
- 18.93
- At average daily volume
Superinvestors holding CMPX, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding CMPX at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Compass Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 (view filing)8:33 AM ET | Nov 17 | 1 day | Lerner NeilChief Accounting Officer | PPurchase | +10.0K | $0.59 | +$5.90K | +2.4%430.0K after | |
| Oct 2, 2026 (view filing)8:00 AM ET | Oct 1 | 1 day | Lerner NeilChief Accounting Officer | PPurchase | +20.0K | $0.92 | +$18.4K | +5.0%420.0K after | |
| Sep 25, 2026 (view filing)8:01 AM ET | Sep 24 | 1 day | Lerner NeilChief Accounting Officer | PPurchase | +2.50K | $1.14 | +$2.85K | +0.6%400.0K after | |
| Apr 30, 2026 (view filing) | Apr 29 | 1 day | Lerner NeilChief Accounting Officer | PPurchase | +15.0K | $1.89 | +$28.4K | +3.9%397.5K after | Amended |
| Apr 30, 2026 (view filing) | Apr 29 | 1 day | Anderman JonathanGeneral Counsel | PPurchase | +25.0K | $1.89 | +$47.3K | +14.6%196.0K after | Amended |
| May 27, 2025 (view filing) | May 27 | Same day | Schuetz Thomas J.CHIEF EXECUTIVE OFFICER | PPurchase | +10.0K | $2.11 | +$21.1K | +0.2%6.48M after | |
| Apr 11, 2025 (view filing)7:24 PM ET | Apr 9 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | SSale | −3.57M | $1.59 | −$5.68M | −100.0%0 after | Duplicate filing |
| Apr 11, 2025 (view filing) | Apr 9 | 2 days | Gordon Carl LDirector, 10% Owner | SSale | −3.57M | $1.59 | −$5.68M | −100.0%0 after | |
| Apr 8, 2025 (view filing) | Apr 7 | 1 day | Anderman JonathanGen Counsel & Corporate Sec | PPurchase | +20.0K | $1.54 | +$30.8K | +2,000.0%21.0K after | |
| Apr 8, 2025 (view filing) | Apr 7 | 1 day | Lerner NeilCHIEF ACCOUNTING OFFICER | PPurchase | +20.0K | $1.42 | +$28.4K | +6.7%320.0K after |
Top 10 13F holders, Q3 2026
See all 171 holdersThe largest institutional positions in Compass Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 17,990,782 | $18.7M | 0.86% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 15,219,994 | $15.8M | 0.29% | 00.0% | Unchanged |
| Suvretta Capital Management, LLC | 14,326,988 | $14.9M | 0.41% | +225,829+1.6% | Added |
| BlackRock, Inc. | 11,394,556 | $11.9M | 0.00% | +112,775+1.0% | Added |
| Enavate Sciences GP, LLC | 7,788,150 | $8.10M | 2.90% | 00.0% | Unchanged |
| State Street Corp | 7,737,938 | $8.05M | 0.00% | −2,215,715−22.3% | Reduced |
| Palo Alto Investors LP | 7,148,673 | $7.43M | 1.11% | +1,316,860+22.6% | Added |
| Vanguard Capital Management LLC | 5,994,782 | $6.23M | 0.00% | −124,000−2.0% | Reduced |
| Millennium Management LLC | 4,686,422 | $4.87M | 0.00% | −26,825−0.6% | Reduced |
| Qube Research & Technologies Ltd | 4,170,894 | $4.34M | 0.00% | +483,405+13.1% | Added |
Holders of 5% or more of CMPX
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Compass Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Tang Capital Management LLC | 13G/A | 9.99%17.2M shares | 0.00 ppfrom 9.99% | Jan 16, 20255 filings | Nov 14, 2025 | SEC |
| OrbiMed Advisors LLC | 13D/A | 8.90%15.2M shares | −2.10 ppfrom 11.00% | Jul 14, 20216 filings | Aug 15, 2025 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 8.20%14.1M shares | +3.00 ppfrom 5.20% | Aug 13, 20252 filings | Aug 21, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.20%9.27M shares | +0.60 ppfrom 4.60% | Feb 4, 20253 filings | Jan 21, 2026 | SEC |